# LUCENCE**INSIGHT**™

## Multi Cancer Early Detection

### Early Detection Saves Lives

*Physician Brochure*

● Traditional screening is recommended only for colorectal, breast, and cervical cancer.[1]

● 4 in 5 cancer deaths are not covered by traditional screening.[2] These arise from unscreened common cancers like lung, liver, and pancreas.



● 5-year survival is higher when cancer is detected early.[3]



● Lucence**INSIGHT**™ is a multi-cancer early detection (MCED) next-generation sequencing test that screens for up to 50 cancers with a single blood draw.

● The test uses Lucence's amplicon-based mirror barcoding technology to detect circulating tumor and viral DNA. It then predicts tumor location with machine learning.

# LucenceINSIGHT™ Screens For Cancers With High Accuracy

Cancer-associated
alterations

Symptoms
onset

Cancer
metastasis

EARLY → LATE

## LucenceINSIGHT™ Specifications[4]

| Sensitivity | Specificity | Limit of detection | Tumor localization accuracy |
|---|---|---|---|
| 81% | 99% | 0.05% VAF | 88% |

## Tumor Marker Protein Screening

False-positive results in
2 in 5 patients over 5 years[5]

---

# Evidence

- LucenceINSIGHT™ reported 100% positive predictive value (PPV) from a prospective real-world cohort of 264 asymptomatic individuals in 2023.[6]

- A performance of 81% sensitivity and 99% specificity was reported from a retrospective cohort of 601 patient samples in 2024.[4]

## Case Study: Stage III Colorectal Cancer[6]

A 60 year old asymptomatic male underwent cancer screening.

LucenceINSIGHT™ detected a *RHOA* G62E at 0.4% VAF. PET-CT showed right colon focal uptake (right figure).

Colonoscopy confirmed adenocarcinoma. Subsequent surgery for curative intent confirmed colorectal cancer.

Focal uptake detected in right ascending colon.

# LucenceINSIGHT™ 50

Turnaround Time: (Working Days) **12**

## *Comprehensive screening of 50 cancers in one go.*

**Head & Neck**
**Nasopharyngeal cancer (EBV+)**
**Oropharyngeal cancer**
(HPV-positive; HPV-negative)
**Laryngeal cancer**
**Salivary gland cancer**

**Non-Hodgkin lymphoma**
(Burkitt's lymphoma; Diffuse
large B-cell lymphoma;
Lymphoplasmacytic lymphoma)
**Hairy cell leukemia**

**Breast cancer**

**Lung cancer**
**Lung neuroendocrine tumor**

**Liver cancer**

**Biliary tract cancer**
(Intrahepatic, Extrahepatic,
Gallbladder)
**Kidney cancer (clear cell)**
**Adult Wilms tumor**

**Small intestine cancer**

**Cervical cancer**
**Endometrial cancer**
**Ovarian cancer**
**Ovarian germ cell &
 stromal tumors**
**Vulvar cancer**

**Soft tissue cancer**
(Angiosarcoma;
Smooth muscle sarcoma)

**Eye cancer**
(Conjunctival melanoma;
Uveal melanoma)

**Esophageal cancer**

**Thyroid cancer**

**Acute myeloid leukemia (AML)**
(AML, NPM1-mutated; AML, other defined genetic
alterations; AML, myelodysplasia-related)
**Mast cell tumor**
**Myeloproliferative neoplasm**
**Myeloma**
**Bone cancer**

**Stomach cancer**
**Stomach neuroendocrine tumor**

**Gastrointestinal
stromal tumor (GIST)**

**Adrenal gland cancer**

**Pancreatic cancer**

**Colorectal cancer**
**Colorectal
neuroendocrine tumor**

**Bladder cancer**

**Penile cancer**
**Prostate cancer**
**Testis cancer**

**Skin cancer**
(Melanoma; Non-melanoma)

---

# For Women

Turnaround Time: (Working Days) **18**

| LucenceINSIGHT™ 12 | LucenceINSIGHT™ Women's 7 |
|---|---|
| covers 12 cancers for women | covers 7 cancers (in pink) |

Nasopharyngeal cancer (EBV+)

**Thyroid cancer**

**Breast cancer**

**Lung cancer**

**Liver cancer**

Stomach cancer

**Pancreatic cancer**

Gastrointestinal
stromal tumor (GIST)

**Colorectal cancer**

**Ovarian cancer**

Cervical cancer
Endometrial cancer

# For Men

Turnaround Time: (Working Days) **18**

| LucenceINSIGHT™ 12 | LucenceINSIGHT™ 5 |
|---|---|
| covers 12 cancers for men | covers 5 cancers (in blue) |

Nasopharyngeal cancer (EBV+)

Esophageal cancer

Thyroid cancer

Lung cancer

Liver cancer

Stomach cancer

Pancreatic cancer

Kidney cancer
(clear cell)

Gastrointestinal
stromal tumor (GIST)

Colorectal cancer

Bladder cancer

Prostate cancer

# LUCENCE**INSIGHT**™

# Recommendations To Patients

● Lucence**INSIGHT**™ is recommended for patients who:

✓ are aged 40+.

✓ have elevated risk of cancer (family history, diet, lifestyle)

● The test is not recommended for patients who:

✖ are pregnant

✖ are in cancer remission for < 3 years

✖ had an allogenic bone transplant or a blood transfusion < 2 weeks prior to sample collection

● No fasting is needed. Patient should refrain from heavy meals 4 hours before.

---

## Distributed By Parkway Laboratories

References:
1. HealthHub. Screen for Life. Singapore Ministry of Health. https://www.healthhub.sg/programmes/screen_for_life/sfl-faqs#home. Accessed October 24 2024.
2. Statistic derived from data reported in Bray, F. et al. CA Cancer J. Clin. 2024; 74(3): 229-263.
3. Statistics derived from data reported in SEER Cancer Stat Facts. https://seer.cancer.gov/statfacts/.
4. Poh, J. et al. J. Clin. Oncol. 2024; 42(16): e15042.
5. Croswell, J. et al. Ann. Fam. Med. 2009; 7(3): 212–222.
6. Tucker, S. et al. Ann. Oncol. 2023; 34: S1625-S1626

Website

Facebook

M6001E-SG-06. November 2024